.Nature Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of clients along with HER2+ innovative bosom cancer as well as active or even steady mind metastases revealed constant intracranial activity as well as wide spread efficacy of T-DXd.